Spero Therapeutics
SPRO
50 hedge funds and large institutions have $143M invested in Spero Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 8 closing their positions.
733% more capital invested
Capital invested by funds: $17.2M → $143M (+$126M)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.81% less ownership
Funds ownership: 26.91% → 26.1% (-0.81%)
7% less funds holding
Funds holding: 54 → 50 (-4)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $29K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$165K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$85.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$38.5K |
| 5 |
Millennium Management
New York
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$72.3K |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$69.4K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$35.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$32K |
| 5 |
HF
HRT Financial
New York
|
-$22K |
SPRO Hedge Fund Activity: Q4 2023 in Review
50 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2023, worth a combined $143M — up 733% from $17.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SPRO and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Anson Funds Management, adding an estimated $165K. The largest seller was Ameriprise, cutting an estimated $72.3K.
- 50 institutional investors held Spero Therapeutics (SPRO) as of Q4 2023, down from 54 in Q3 2023.
- Funds reported $143M of Spero Therapeutics stock for Q4 2023, up 733% quarter-over-quarter.
- 6 funds opened new Spero Therapeutics positions in Q4 2023 and 8 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q4 2023 was Anson Funds Management, an estimated $165K added.
- The largest Spero Therapeutics seller in Q4 2023 was Ameriprise, an estimated $72.3K sold.
Based on aggregated 13F filings for Q4 2023.